Nanobiotix S.A. (NBTX) - 9.86 USD

Nanobiotix S.A. - NBTX 9.86 USD

EPS

-1.69

P/B

-6.60

Beta

1.58

Target Price

7.64 USD

9.860 USD

Daily: -0.90%

1M 6M YTD 1Y 2Y 5Y Max

Key Metrics

EPS: -1.69

Book Value: -1.39

Price to Book: -6.60

Estimates

Forward P/E: -3.63

Forward EPS: -2.52

Target Mean Price: 7.64

DCF Valuation

Tweak assumptions to recompute fair value for Nanobiotix S.A. (NBTX)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

About Nanobiotix S.A. - (NBTX)

Country: France

Sector: Health Care

Website: http://www.nanobiotix.com

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Exchange Ticker

NMS (United States) NBTX

No dividends available.

Dividends

Historical Split Corporate Actions

No corporate actions available.

Trades

My Trades

Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans